» Articles » PMID: 38405061

Epigenetic Modifications in Obesity-associated Diseases

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2024 Feb 26
PMID 38405061
Authors
Affiliations
Soon will be listed here.
Abstract

The global prevalence of obesity has reached epidemic levels, significantly elevating the susceptibility to various cardiometabolic conditions and certain types of cancer. In addition to causing metabolic abnormalities such as insulin resistance (IR), elevated blood glucose and lipids, and ectopic fat deposition, obesity can also damage pancreatic islet cells, endothelial cells, and cardiomyocytes through chronic inflammation, and even promote the development of a microenvironment conducive to cancer initiation. Improper dietary habits and lack of physical exercise are important behavioral factors that increase the risk of obesity, which can affect gene expression through epigenetic modifications. Epigenetic alterations can occur in early stage of obesity, some of which are reversible, while others persist over time and lead to obesity-related complications. Therefore, the dynamic adjustability of epigenetic modifications can be leveraged to reverse the development of obesity-associated diseases through behavioral interventions, drugs, and bariatric surgery. This review provides a comprehensive summary of the impact of epigenetic regulation on the initiation and development of obesity-associated cancers, type 2 diabetes, and cardiovascular diseases, establishing a theoretical basis for prevention, diagnosis, and treatment of these conditions.

Citing Articles

Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link.

Abdulla A, Sadida H, Jerobin J, Elfaki I, Mir R, Mirza S J Natl Cancer Cent. 2025; 5(1):8-27.

PMID: 40040878 PMC: 11873641. DOI: 10.1016/j.jncc.2024.11.001.


From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections.

Sarmento-Cabral A, Fuentes-Fayos A, Ordonez F, Leon-Gonzalez A, Martinez-Fuentes A, Gahete M Rev Endocr Metab Disord. 2025; .

PMID: 39910005 DOI: 10.1007/s11154-025-09948-7.


Kdm2a inhibition in skeletal muscle improves metabolic flexibility in obesity.

Wang Y, Xie H, Liu Q, Wang N, Luo X, Sun F Nat Metab. 2025; 7(2):383-400.

PMID: 39870955 PMC: 11860252. DOI: 10.1038/s42255-024-01210-9.


Epigenetic modifications in obesity-associated diseases.

Long Y, Mao C, Liu S, Tao Y, Xiao D MedComm (2020). 2024; 5(2):e496.

PMID: 38405061 PMC: 10893559. DOI: 10.1002/mco2.496.

References
1.
Mendoza-Perez J, Gu J, Herrera L, Tannir N, Zhang S, Matin S . Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017; 123(18):3617-3627. PMC: 5589484. DOI: 10.1002/cncr.30707. View

2.
Baca P, Barajas-Olmos F, Mirzaeicheshmeh E, Zerrweck C, Guilbert L, Sanchez E . DNA methylation and gene expression analysis in adipose tissue to identify new loci associated with T2D development in obesity. Nutr Diabetes. 2022; 12(1):50. PMC: 9763387. DOI: 10.1038/s41387-022-00228-w. View

3.
Choi Y, Jeon S, Shin S . Impact of a Ketogenic Diet on Metabolic Parameters in Patients with Obesity or Overweight and with or without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2020; 12(7). PMC: 7400909. DOI: 10.3390/nu12072005. View

4.
Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

5.
Yang P, Hou P, Liu F, Hong W, Chen H, Sun X . Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression. Proc Natl Acad Sci U S A. 2020; 117(44):27412-27422. PMC: 7959534. DOI: 10.1073/pnas.2002997117. View